The U.S. Food and Drug Administration (FDA) has approved a drug called Vascepa that is believed to be used to treat patients with very high levels of triglycerides,media reported. The drug has some important differences from common fish oil supplements and the prescription omega-3, and based on studies, the drug may also have the same effect as other statins to protect heart disease patients.
Vascepa is a prescription ethyl ethyl for e-EPA, a substance that is used as a drug for groups with very high levels of triglycerides. According to the FDA, the drug could also be used as an adjunct to angiotensin in his statin treatment. Using more than 8,000 people over the age of 45 with coronary heart disease and diabetes, the FDA found that the drug could reduce the risk of heart attacks and strokes in these patients.
This is the first time the FDA has approved EPA-based prescription treatments. Unlike fish oil and omega-3 supplements sold on the counter, Vascepa contains EPA without DHA ingredients — which may increase cholesterol levels, which is a problem for patients with very high levels of triglycerides, who typically have high LDL bad cholesterol levels.